1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > CIS Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting, Type I & II Diabetes, Analogs, Recombinant Insulin) Analysis And Segment Forecasts To 2020

The CIS market for insulin and insulin products is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.

Further Key findings from the study suggest:

Regionally, Russia occupied the largest share of the market, accounting for 69.2% of the revenue. Its large share is majorly attributed by the subsidies that Russian government provides to make insulin more affordable for patients.

Ukraine is expected to register the fastest CAGR of 15.6% during the forecast period due to the presence of high untapped opportunities and encouraging government initiatives.

In addition, Poland is expected to grow at a lucrative rate during the forecast period majorly owing to the presence of high diabetes prevalence coupled with increasing healthcare expenditures.

Long acting insulin accounted for the largest share of the market, at over 39.0% in 2013, owing to the higher preference given to long acting insulin therapy for diabetes which results in lesser episodes of low blood sugar. It is also expected that this product segment will grow at the fastest CAGR of over 18.0% during the next six years.

Application of insulin for control of type II diabetes occupied for over 90.0% of the market owing to the presence of larger portfolio of products catering to this segment and a relatively larger prevalence base

Analogs accounted for over 80.0% of the revenue owing to their relatively higher prices and better efficacy levels. In addition, this segment is expected to exhibit the fastest CAGR during the forecast period on account of the introduction of technologically advanced products such as ultra-long and ultra-fast acting analogs.

For the purpose of this study, Grand View Research has segmented the CIS Insulin market on the basis of product, application, source and region:

- CIS Insulin Product Outlook
- Rapid Acting
- Long Acting
- Premixed
- Premixed Analog
- Short Acting
- Intermediate Acting
- CIS Insulin Application Outlook
- Type II Diabetes
- Type I Diabetes
- CIS Insulin Source Outlook
- Human Recombinant
- Analogs
- CIS Insulin Regional Outlook
- Russia
- Poland
- Turkey
- Ukraine
- Uzbekistan
- Belarus
- Kazakhstan
- Rest of CIS

Table Of Contents

CIS Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting, Type I and II Diabetes, Analogs, Recombinant Insulin) Analysis And Segment Forecasts To 2020
Table of Contents

Chapter 1. Executive Summary

1.1. CIS Insulin - Industry Summary and Critical Success Factors (CSFs)

Chapter 2. CIS Insulin Industry Outlook

2.1. Market Segmentation

2.2. Market Size and Growth Prospects

2.3. CIS Insulin Market Dynamics

2.3.1. Market Driver Analysis

2.3.2. Market Restraint Analysis

2.4. Key Opportunities Prioritized

2.5. Industry Analysis - Porter's

2.6. CIS Insulin - Company Market Share Analysis

2.7. CIS Insulin Market PESTEL Analysis, 2012

2.8. CIS Insulin - Pipeline Overview

Chapter 3. CIS Insulin Product Outlook, Volume (number of units) and Value (USD Million) Estimates and Forecasts, 2012 - 2020

3.1. Rapid Acting Analog

3.1.1.1. Pricing Analysis (Average Selling Price in USD), 2012 - 2020

3.2. Short Acting Insulin

3.2.1.1. Pricing Analysis (Average Selling Price in USD), 2012 - 2020

3.3. Intermediate Acting Insulin

3.3.1.1. Pricing Analysis (Average Selling Price in USD), 2012 - 2020

3.4. Long Acting Analog

3.4.1.1. Pricing Analysis (Average Selling Price in USD), 2012 - 2020

3.5. Pre-Mixed

3.5.1.Pre-Mixed Insulin Market Estimates and Forecasts

3.5.1.1. Pricing Analysis (Average Selling Price in USD), 2012 - 2020

3.5.2.Pre-Mixed Analog Market Estimates and Forecasts

3.5.2.1. Pricing Analysis (Average Selling Price in USD), 2012 - 2020

Chapter 4. CIS Insulin Segment (on the basis of source) Outlook, Volume (number of units) and Value (USD Million) Estimates and Forecasts, 2012 - 2020

4.1. Insulin Analogs

4.1.1.Insulin Analogs Market Estimates and Forecasts

4.2. Human Recombinant Insulin

4.2.1. Human Recombinant Insulin Market Estimates and Forecasts

Chapter 5. CIS Insulin Application Outlook(USD Million) Estimates and Forecasts, 2012 - 2020

5.1. Type I and Other Diabetes

5.1.1. Type I and Other Diabetes Market Estimates and Forecasts

5.2. Type II Diabetes

5.2.1. Type II Diabetes Market Estimates and Forecasts

Chapter 6. Insulin Regional Outlook, Volume (number of units) and Value (USD Million) Estimates and Forecasts, 2012 - 2020

6.1. Russia

6.1.1. Russia Insulin Market, by Products

6.1.2. Russia Insulin Market, by Applications (only revenue)

6.1.3. Russia Insulin Market, by Source

6.2. Poland

6.2.1. Poland Insulin Market, by Products

6.2.2. Poland Insulin Market, by Applications (only revenue)

6.2.3. Poland Insulin Market, by Source

6.3. Turkey

6.3.1. Turkey Insulin Market, by Products

6.3.2. Turkey Insulin Market, by Applications (only revenue)

6.3.3. Turkey Insulin Market, by Source

6.4. Ukraine

6.4.1. Ukraine Insulin Market, by Products

6.4.2. Ukraine Insulin Market, by Applications (only revenue)

6.4.3. Ukraine Insulin Market, by Source

6.5. Uzbekistan

6.5.1. Uzbekistan Insulin Market, by Products

6.5.2. Uzbekistan Insulin Market, by Applications (only revenue)

6.5.3. Uzbekistan Insulin Market, by Source

6.6. Belarus

6.6.1. Belarus Insulin Market, by Products

6.6.2. Belarus Insulin Market, by Applications (only revenue)

6.6.3. Belarus Insulin Market, by Source

6.7. Kazakhstan

6.7.1. Kazakhstan Insulin Market, by Products

6.7.2. Kazakhstan Insulin Market, by Applications (only revenue)

6.7.3. Kazakhstan Insulin Market, by Source

6.8. Rest of CIS

6.8.1. Rest of CIS Insulin Market, by Products

6.8.2. Rest of CIS Insulin Market, by Applications (only revenue)

6.8.3. Rest of CIS Insulin Market, by Source



Companies analysed in competitive landscape

Novo Nordisk
Sanofi
Eli Lilly
Bristol-Myers Squibb
Novartis
Takeda Pharmaceuticals
Boehringer Ingelheim
Biocon
Dongbao Enterprise Group Co., Ltd.
Merck KGaA
Oramed Pharmaceuticals Inc.
Halozyme Therapeutics
Wanbang Biopharma
Xinbai Pharmaceutical
Gan and Lee Pharmaceutical
Indrar
Farmak

List of Tables

CIS Insulin- Industry summary and Critical Success Factors (CSFs)
CIS Insulin Market, by Countries, 2012 - 2020 (USD Million)
CIS Insulin Market, by Products, 2012 - 2020 (USD Million)
CIS Insulin Market, by Products, 2012 - 2020 (‘000 Units)
CIS Insulin Market, by Applications, 2012 - 2020 (USD Million)
CIS Insulin Market, by Source Types, 2012 - 2020 (USD Million)
CIS Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Russia Insulin Market, by Products, 2012 - 2020 (USD Million)
Russia Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Russia Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Russia Insulin Market, by Source Types, 2012 - 2020 (USD million)
Russia Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Russia Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)
Poland Insulin Market, by Products, 2012 - 2020 (USD Million)
Poland Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Poland Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Poland Insulin Market, by Source Types, 2012 - 2020 (USD million)
Poland Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Poland Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)
Turkey Insulin Market, by Products, 2012 - 2020 (USD Million)
Turkey Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Turkey Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Turkey Insulin Market, by Source Types, 2012 - 2020 (USD million)
Turkey Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Turkey Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)
Ukraine Insulin Market, by Products, 2012 - 2020 (USD Million)
Ukraine Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Ukraine Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Ukraine Insulin Market, by Source Types, 2012 - 2020 (USD million)
Ukraine Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Ukraine Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)
Uzbekistan Insulin Market, by Products, 2012 - 2020 (USD Million)
Uzbekistan Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Uzbekistan Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Uzbekistan Insulin Market, by Source Types, 2012 - 2020 (USD million)
Uzbekistan Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Uzbekistan Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)
Belarus Insulin Market, by Products, 2012 - 2020 (USD Million)
Belarus Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Belarus Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Belarus Insulin Market, by Source Types, 2012 - 2020 (USD million)
Belarus Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Belarus Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)
Kazakhstan Insulin Market, by Products, 2012 - 2020 (USD Million)
Kazakhstan Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Kazakhstan Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Kazakhstan Insulin Market, by Source Types, 2012 - 2020 (USD million)
Kazakhstan Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Kazakhstan Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)
Rest of CIS Insulin Market, by Products, 2012 - 2020 (USD Million)
Rest of CIS Insulin Prices, by Product Type, 2012 - 2020 (USD/Unit)
Rest of CIS Insulin Market, by Product Types, 2012 - 2020 ('000 units)
Rest of CIS Insulin Market, by Source Types, 2012 - 2020 (USD million)
Rest of CIS Insulin Market, by Source Types, 2012 - 2020 (‘000 Units)
Rest of CIS Insulin Market, by Diabetes Types, 2012 - 2020 (USD Million)

List of Figures

CIS InsulinMarket Segmentation
CIS InsulinMarket Revenue, 2012 - 2020
CIS InsulinMarket Dynamics
CIS InsulinCompany Market Share Analysis, 2012
Key Opportunities Prioritized
Industry Analysis - Porter's
CIS InsulinPESTEL Analysis, 2012
CIS Insulinmarket - company market share analysis, 2013 (%)
CIS insulin market, by product type, 2012 - 2020
CIS insulin market, by source types, 2012 - 2020
CIS insulin market, by applications, 2012 - 2020

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Type 2 Diabetes Mellitus: KOL Insight 2016

Type 2 Diabetes Mellitus: KOL Insight 2016

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists ...

European Market Report for Modern Insulin 2016 - MedCore

European Market Report for Modern Insulin 2016 - MedCore

  • $ 5995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern ...

US Market Report for Insulin 2017 - MedCore

US Market Report for Insulin 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.